Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Malignant Melanoma

  Free Subscription


Articles published in Nat Med

Retrieve available abstracts of 25 articles:
HTML format



Single Articles


    June 2025
  1. MONSON KR, Ferguson R, Handzlik JE, Morales L, et al
    Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanoma.
    Nat Med. 2025 Jun 5. doi: 10.1038/s41591-025-03699.
    PubMed     Abstract available


    May 2025
  2. MIGLINO N, Toussaint NC, Ring A, Bonilla X, et al
    Feasibility of multiomics tumor profiling for guiding treatment of melanoma.
    Nat Med. 2025 May 27. doi: 10.1038/s41591-025-03715.
    PubMed     Abstract available


    January 2025
  3. DUMMER R, Robert C, Scolyer RA, Taube JM, et al
    Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB-D melanoma: a phase 1/2 trial.
    Nat Med. 2025 Jan 7. doi: 10.1038/s41591-024-03411.
    PubMed     Abstract available


  4. BORGERS JSW, Lenkala D, Kohler V, Jackson EK, et al
    Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial.
    Nat Med. 2025 Jan 3. doi: 10.1038/s41591-024-03418.
    PubMed     Abstract available


    June 2024
  5. LONG GV, Carlino MS, Au-Yeung G, Spillane AJ, et al
    Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAF(V600)-mutant resectable melanoma: the randomized phase 2 NeoTrio trial.
    Nat Med. 2024 Jun 21. doi: 10.1038/s41591-024-03077.
    PubMed     Abstract available


  6. O'LEARY K
    Neoadjuvant immunotherapy a new standard of care for melanoma.
    Nat Med. 2024 Jun 17. doi: 10.1038/d41591-024-00045.
    PubMed    


    February 2024
  7. BJORK JR, Bolte LA, Maltez Thomas A, Lee KA, et al
    Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma.
    Nat Med. 2024 Feb 16. doi: 10.1038/s41591-024-02803.
    PubMed     Abstract available


    January 2024
  8. O'LEARY K
    Personalized mRNA vaccine boosts melanoma immunotherapy.
    Nat Med. 2024 Jan 25. doi: 10.1038/d41591-024-00006.
    PubMed    


  9. KIRKWOOD JM, Del Vecchio M, Weber J, Hoeller C, et al
    Author Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.
    Nat Med. 2024 Jan 4. doi: 10.1038/s41591-023-02775.
    PubMed    


    November 2023
  10. FRATERMAN I, Reijers ILM, Dimitriadis P, Broeks A, et al
    Association between pretreatment emotional distress and neoadjuvant immune checkpoint blockade response in melanoma.
    Nat Med. 2023 Nov 13. doi: 10.1038/s41591-023-02631.
    PubMed     Abstract available


  11. ROUTY B, Lenehan JG, Miller WH Jr, Jamal R, et al
    Author Correction: Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial.
    Nat Med. 2023 Nov 3. doi: 10.1038/s41591-023-02650.
    PubMed    


  12. KIRKWOOD JM, Del Vecchio M, Weber J, Hoeller C, et al
    Publisher Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.
    Nat Med. 2023 Nov 3. doi: 10.1038/s41591-023-02661.
    PubMed    


    October 2023
  13. KIRKWOOD J, Del Vecchio M, Weber J, Hoeller C, et al
    Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.
    Nat Med. 2023 Oct 16. doi: 10.1038/s41591-023-02583.
    PubMed     Abstract available


    August 2023
  14. VANDERWALDE A, Bellasea SL, Kendra KL, Khushalani NI, et al
    Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial.
    Nat Med. 2023 Aug 17. doi: 10.1038/s41591-023-02498.
    PubMed     Abstract available


  15. CARVALHO T
    Personalized anti-cancer vaccine combining mRNA and immunotherapy tested in melanoma trial.
    Nat Med. 2023 Aug 16. doi: 10.1038/d41591-023-00072.
    PubMed    


  16. BARATA C, Rotemberg V, Codella NCF, Tschandl P, et al
    A reinforcement learning model for AI-based decision support in skin cancer.
    Nat Med. 2023;29:1941-1946.
    PubMed     Abstract available


    July 2023
  17. ROUTY B, Lenehan JG, Miller WH Jr, Jamal R, et al
    Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial.
    Nat Med. 2023 Jul 6. doi: 10.1038/s41591-023-02453.
    PubMed     Abstract available


  18. BRASTIANOS PK, Kim AE, Giobbie-Hurder A, Lee EQ, et al
    Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results.
    Nat Med. 2023;29:1728-1737.
    PubMed     Abstract available


    May 2023
  19. GARBE C, Dummer R, Amaral T, Amaria RN, et al
    Neoadjuvant immunotherapy for melanoma is now ready for clinical practice.
    Nat Med. 2023 May 16. doi: 10.1038/s41591-023-02336.
    PubMed    


    April 2023
  20. LIU S, Dharanipragada P, Lomeli SH, Wang Y, et al
    Multi-organ landscape of therapy-resistant melanoma.
    Nat Med. 2023 Apr 27. doi: 10.1038/s41591-023-02304.
    PubMed     Abstract available


  21. GLITZA OLIVA IC, Ferguson SD, Bassett R Jr, Foster AP, et al
    Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results.
    Nat Med. 2023;29:898-905.
    PubMed     Abstract available


    March 2023
  22. O'LEARY K
    Earlier appears better for immunotherapy in melanoma.
    Nat Med. 2023 Mar 16. doi: 10.1038/d41591-023-00028.
    PubMed    


  23. CASCONE T, Leung CH, Weissferdt A, Pataer A, et al
    Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial.
    Nat Med. 2023 Mar 16. doi: 10.1038/s41591-022-02189.
    PubMed     Abstract available


    February 2023
  24. TIAN J, Chen JH, Chao SX, Pelka K, et al
    Combined PD-1, BRAF and MEK inhibition in BRAF(V600E) colorectal cancer: a phase 2 trial.
    Nat Med. 2023;29:458-466.
    PubMed     Abstract available


  25. NIKNAFS N, Balan A, Cherry C, Hummelink K, et al
    Persistent mutation burden drives sustained anti-tumor immune responses.
    Nat Med. 2023;29:440-449.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.